Brilinta
E505483
P2Y12 receptor antagonist
antiplatelet medication
pharmaceutical drug
platelet aggregation inhibitor
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
P2Y12 receptor antagonist
ⓘ
antiplatelet medication ⓘ pharmaceutical drug ⓘ platelet aggregation inhibitor ⓘ |
| affectsBiologicalProcess | platelet aggregation ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| commonAdverseEffect |
bleeding
ⓘ
bruising ⓘ dyspnea ⓘ epistaxis ⓘ |
| contraindicatedIn |
active pathological bleeding
ⓘ
history of intracranial hemorrhage ⓘ |
| contraindicatedWith |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| developedBy | AstraZeneca NERFINISHED ⓘ |
| firstApprovedYearUS | 2011 ⓘ |
| hasActiveIngredient | ticagrelor NERFINISHED ⓘ |
| hasAdministrationFrequency | twice daily ⓘ |
| hasATCCode | B01AC24 ⓘ |
| hasBlackBoxWarning | risk of bleeding ⓘ |
| hasDosageForm | oral tablet ⓘ |
| hasDrugClass |
P2Y12 inhibitor
ⓘ
antiplatelet agent ⓘ platelet aggregation inhibitor ⓘ |
| hasGenericName | ticagrelor NERFINISHED ⓘ |
| hasHalfLife |
approximately 7 hours for ticagrelor
ⓘ
approximately 9 hours for active metabolite ⓘ |
| hasMechanismOfAction | reversible inhibition of P2Y12 ADP receptor on platelets ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStrength |
60 mg tablet
ⓘ
90 mg tablet ⓘ |
| indicatedFor |
ST-elevation myocardial infarction
ⓘ
acute coronary syndrome ⓘ history of myocardial infarction ⓘ non–ST-elevation myocardial infarction ⓘ reduction of cardiovascular death ⓘ reduction of heart attack risk ⓘ reduction of stroke risk ⓘ unstable angina ⓘ |
| isPrescriptionOnly | true ⓘ |
| marketedAs |
Brilique
NERFINISHED
ⓘ
Possia NERFINISHED ⓘ |
| metabolizedBy |
CYP3A4
ⓘ
CYP3A5 NERFINISHED ⓘ |
| pregnancyCategoryUS | not assigned (use only if clearly needed) ⓘ |
| reduces | platelet activation ⓘ |
| requiresCoAdministration | low-dose aspirin in most indications ⓘ |
| usedWith | aspirin ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.